# Neutralizing Interleukin (IL)-6

> **NCT07493317** · PHASE2 · RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 60 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT07493317
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-26
- **Primary completion:** 2031-02-06
- **Final completion:** 2031-02-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07493317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07493317, "Neutralizing Interleukin (IL)-6". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07493317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*